Hydralazine injection warnings: Difference between revisions

Latest revision as of 22:10, 21 July 2014

Redirect to:

@@ Line 1: / Line 1: @@
-__NOTOC__
+#REDIRECT [[Hydralazine#Warnings]]
-{{Hydralazine}}
-{{CMG}}; {{AE}} {{AK}}
-==Warnings==
-In a few patients, hydralazine may produce a clinical picture simulating [[systemic lupus erythematosus]] including [[glomerulonephritis]].  In such patients, hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug.  Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later.  Long-term treatment with steroids may be necessary (see [[Hydralazine injection precautions|PRECAUTIONS, Laboratory Tests]]).<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3797028-c625-4f70-ae69-8a5f6f23f1b8 | publisher =  | date =  | accessdate = 10 March 2014 }}</ref>
-==References==
-{{Reflist|2}}
-[[Category:Cardiovascular Drugs]]
-[[Category:Drugs]]